Once-daily treatment for canine atopic dermatitis
Delivers 6-in-1 parasite protection for cats
Valuable discounts, expert information, and tips
See how injectable medications offer value beyond the prescription
The first and only FDA-Approved veterinary antiemetic
The first long-lasting monoclonal antibody therapy for canine atopic dermatitis
Vaccination for the prevention of respiratory disease caused by BRSV
The beef industry’s No. 1 branded preconditioning program
Exclusive pricing program for Cattle producers
Outstanding protection against costly respiratory and reproductive diseases
Treatment and control of gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites
Innovative food safety products that help deliver a farm-to-fork solution for beef
The most comprehensive guarantee available
First and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses
Annual vaccination with CORE EQ INNOVATOR helps provide the protection your horse needs
Treats and controls encysted small strongyles, bots and roundworms. QUEST PLUS contains an additional active ingredient for efficacy against tapeworms
Patented and scientific method of determining fair service pricing to improve your clinic's profitability
Connect directly to valuable dairy management resources and experts
The most "veterinarian recommended" and "producer used" prostaglandin in the market
Delivers the peace of mind and profitability that come with no milk discard
Effective and convenient treatment for acute metritis in cattle
Working together to improve reproduction
One injection treats and controls swine respiratory disease for 7 days
Protect sows and gilts from costly breeding herd diseases — parvovirus, leptospirosis and erysipelas
The industry standard for in ovo technology.
Full automation solutions for hatchery automation
Prevention and control of necrotic enteritis, increased rate of weight gain and improved feed efficiency in poultry
for the prevention of coccidiosis in poultry
modified-live vaccine that helps poultry companies reduce their overall Salmonella load
Blood glucose monitoring system
Smart new diagnostics platform that can reinvent your in-house diagnostic routines
Detect Johne’s Disease with confidence in cattle and goat herds
Simple and effective detection of a deadly Feline Virus
Accurate, affordable and easy to use
Order Beef Genetics products online
Order Dairy Genetics products online
Delivers reliable predictions of genetic merit based on test results of core traits
Represents the latest advancement in Angus genotyping technology.
Register today to learn more
Become a more effective leader
Looking for a tailored experience?
Earn continuing education credits and stay current on industry developments with Zoetis’ convenient, on-demand learning solutions.
Veterinarians, Veterinarian Techs, Business Owners, and Farm Hands
Launch your veterinary career
Veterinarian Students and Recent Graduates
Animal health expertise and results-focused resources for high-performing teams and leaders.
Veterinarians, Dairy producers, Beef producers, Equine Specialists, Pork producers, Poultry producers, Managers, Business Owners and Staff
Home / NEWS & MEDIA / On-Arrival Vaccination Research Shows Benefit to Bottom Line
By Douglas Hilbig, DVM, Beef Zoetis Technical Services
Giving an antibiotic to high-risk cattle on-arrival helps control bovine respiratory disease (BRD) in stocker and feedlot operations. While this offers an effective approach, recently we asked the question, would vaccination on-arrival reduce illness and death due to BRD?
In most stocker and feedlot operations there is a 30- to 60-day starter phase, where cattle are acclimated to their new surroundings and the health is monitored closely. Standard practice is to vaccinate shortly after arrival and boost two weeks later. In many cases, the arrival antibiotic can mask the lack of effect the arrival vaccination program has, so health problems are assumed to be due to resistance of the on arrival antibiotic, not the lack of effectiveness of the vaccination program.
Oklahoma State University recently published the results from a 60-day trial where more than 1,400 high-risk calves were assigned to one of three vaccine protocols on-arrival at the feedlot.1 The calves in this study were not given an antibiotic on-arrival. Health and performance outcomes were measured to show the differences between the groups.
The three vaccine groups were:• INFORCE™ 3 and ONE SHOT® BVD on-arrival; booster 14 days later with BOVI-SHIELD GOLD® 5 • Pyramid® 5 + Presponse® SQ on-arrival; booster 14 days later with Pyramid® 5• Vista® Once SQ on-arrival; booster 14 days later Vista® 5
The INFORCE 3 and ONE SHOT BVD group was given an intranasal modified-live viral (MLV) vaccine for bovine herpesvirus 1 (the virus that causes infectious bovine rhinotracheitis—IBR), bovine respiratory syncytial virus (BRSV) and parainfluenza 3 (PI3) virus, in addition to an injectable MLV vaccine for bovine viral diarrhea (BVD) virus types 1 and 2, and M. haemolytica. The other two groups were given an injectable combination MLV respiratory and M. haemolytica vaccine.
It was expected several calves would need a first BRD treatment in the first 10 days of the study, since vaccines require time for the calves’ immune systems to mount a response. There was no statistical difference at the first treatment between the groups. The real difference between the groups occurs when looking at the percentage of calves needing a second and third BRD treatment.
The INFORCE 3 and ONE SHOT BVD group showed significantly less (p-value = 0.01) second and third treatments when compared to Vista Once SQ. INFORCE 3 and ONE SHOT BVD had measurably less mortality when compared to Pyramid 5 + Presponse SQ and Vista Once SQ.
Although the regimen using INFORCE 3 and ONE SHOT BVD required the greatest initial cost, the reduction in mortality losses experienced by the calves vaccinated with INFORCE 3 and ONE SHOT BVD resulted in an overall per-head benefit of $16.87 and $32.49 compared to calves vaccinated with Pyramid 5 + Presponse SQ and Vista Once SQ, respectively.
The study confirms that on arrival vaccination “protocol” of high risk calves impacts re-treatment and mortality rates. The other take-home from the study is that a protocol with an intranasal viral vaccination can result in improved well-being and better cattle performance. If you want to look closer at the data behind the results, you may view the complete study online.
As margins continue to tighten, the importance increases for stocker and feedlot managers to evaluate every program. If you have additional questions, I encourage you to visit with your Zoetis representative or veterinarian.
About the author: Douglas Hilbig is a veterinarian with Zoetis Technical Services. Prior to joining Zoetis, Dr. Hilbig spent 22 years as a Veterinary Consultant for feedyard and stocker clients in Kansas and Oklahoma. He started and owned a mixed practice and consulting service in Lakin, KS.
About ZoetisZoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetisUS.com.
For more information, contact:Leona Ling FergusonZoetis973-443-3419
Lori MaudeBader Rutter303email@example.com
Reference :1 Step DL, Krehbiel CR, Hixon C, et al. Evaluation of Commercially Available Multivalent Modified-Live Viral Vaccines on Health and Performance in Feedlot Cattle. Jacobs J Vaccine Vaccination. 2015, 1(2): 1-8.
Mon–Fri, 8am–8pm ET
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.
This site is intended for U.S. Animal Healthcare Professionals.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2017 Zoetis Services LLC. All rights reserved.